PPARG Negatively Modulates Six2 in Tumor Formation of Clear Cell Renal Cell Carcinoma.
暂无分享,去创建一个
T. Song | Mingwei Liu | Yafei Wu | Jianing Liu | Yamin Liu | Dongsheng Ni | Yuping Gu | Yajun Xie | Lei Chen | Qianyin Li | Qingling He | Qin Zhou | Yanxia Hu
[1] Jian-hua Li,et al. Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cells. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[2] D. Steger,et al. PPARγ is dispensable for clear cell renal cell carcinoma progression , 2018, Molecular metabolism.
[3] A. Oshlack,et al. Haploinsufficiency for the Six2 gene increases nephron progenitor proliferation promoting branching and nephron number. , 2017, Kidney international.
[4] Evita T. Sadimin,et al. Renal cell carcinoma: the search for a reliable biomarker. , 2017, Translational cancer research.
[5] Y. Weng,et al. TβRII Regulates the Proliferation of Metanephric Mesenchyme Cells through Six2 In Vitro , 2017, International journal of molecular sciences.
[6] Charles Swanton,et al. Renal cell carcinoma , 2017, Nature Reviews Disease Primers.
[7] B. Saez,et al. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action , 2017, Targeted Oncology.
[8] Yue Zhou,et al. Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[9] N. Samadi,et al. Six Family of Homeobox Genes and Related Mechanisms in Tumorigenesis Protocols , 2016, Tumori.
[10] G. Ayers,et al. SIX2 Effects on Wilms Tumor Biology1 , 2014, Translational oncology.
[11] B. Grygiel-Górniak. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review , 2014, Nutrition Journal.
[12] J. M. Suh,et al. PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.